Dry Eye

NDA Submitted for Dry Eye Disease Treatment KPI-121 0.25%

By October 16, 2018

The NDA includes data from one Phase 2 and two Phase 3 clinical trials (STRIDE 1 and STRIDE 2) involving ~2000 individuals with dry eye disease.

FDA Approves Cequa for the Treatment of Dry Eye Disease

By August 16, 2018

Cequa was evaluated in 2 multicenter, randomized studies involving 1,048 patients with dry eye disease.

Refresh Repair Lubricant Eye Drops Now Available for Dry Eye

By July 10, 2018

The new ocular drops contain carboxymethylcellulose (CMC) 0.5%, hyaluronic acid (HA), glycerin 0.9%, and other organic osmoprotectants.

n-3 Fatty Acids Don't Seem to Be of Any Benefit in Dry Eye Disease

April 16, 2018

Patients randomized to n-3 supplementation did not have significantly better outcomes versus placebo

Rohto Dry-Aid Now Available for Dry Eye Relief

By July 12, 2017

The micro-emulsion contains povidone 0.68% and propylene glycol 0.3%, which work by mimicking a natural tear to restore moisture to the tear film for up to 12 hours.

Refresh Optive Mega-3 Available for Dry Eye Relief

By June 27, 2017

All Optive products have the patented osmoprotectant formula comprised of three solutes: glycerin, I-carnitine, and erythritol.

Novel Tear Production Stimulator Given All Clear by FDA

By April 25, 2017

Safety and efficacy of the TrueTear device were demonstrated in two clinical studies in a total of 145 individuals with aqueous deficient dry eye.

Chronic Dry Eye Med Available in Preservative-Free, Multidose Form

By March 22, 2017

Restasis, a calcineurin inhibitor immunosuppressant, helps increase the eyes' natural ability to produce tears in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.

Supplement May Protect Corneal Nerves In Dry Eye

March 21, 2017

Compared with the placebo group, the ω-3 EFA group had a greater reduction in Ocular Surface Disease Index score and tear osmolarity at day 90 versus baseline.

Positive Phase 3 Results for Dry Eye Disease Candidate

By January 04, 2017

Sun Pharma announced successful Phase 3 results for Seciera (cyclosporine A, 0.09% ophthalmic solution), for the treatment of dry eye disease. Seciera is a preservative-free, aqueous solution with a proprietary nanomicellar formulation of cyclosporine A 0.09%.

New Eye Problems Reported by Some After LASIK

December 05, 2016

Nine out of 10 laser in situ keratomileusis (LASIK) patients report satisfaction afterwards, although a sizable percentage experience new visual disturbances up to six months after the procedure, according to research published online in JAMA Ophthalmology.

FDA Approves Restasis MultiDose

By October 28, 2016

Restasis, a calcineurin inhibitor immunosuppressant, is indicated to increase tear production.

FDA to Review Device-Based Approach for Tear Production

By July 18, 2016

Allergan announced the submission of a de novo application to the Food and Drug Administration (FDA) for the Oculeve Intranasal Tear Neurostimulator device.

First-in-Class Eye Drops Approved to Treat Dry Eye Disease

By July 12, 2016

Shire announced that the Food and Drug Administration (FDA) has approved Xiidra (lifitegrast ophthalmic solution) 5% for the treatment of the signs and symptoms of dry eye disease in adults. This is the first prescription ophthalmic solution approved to treat both signs and symptoms of this condition.

Is Dry Eye Syndrome Associated With Vitamin D?

February 10, 2016

Vitamin D deficiency is associated with dry eye and impaired tear function, according to a study published in the January issue of the International Journal of Rheumatic Diseases.

Dry Eye Disease Often Diagnosed in Alopecia Areata

October 30, 2015

T-cell mediated autoimmunity plays role in etiopathogenesis of alopecia areata, dry eye disease

Lifitegrast Improves Dry Eye Symptoms, Study Finds

By October 27, 2015

Shire announced positive topline results from OPUS-3, a Phase 3 efficacy and safety study of lifitegrast for the treatment of signs and symptoms for dry eye disease.

Refresh Optive Gel Drops Launched for Dry Eye

By October 21, 2015

Allergan announced the launch of Refresh Optive Gel Drops, a new aqueous gel indicated for patients who require or desire a more viscous artificial tear option to relieve dry eye symptoms.

FDA Issues Complete Response Letter for Dry Eye Tx

By October 19, 2015

The FDA has issued a complete response letter (CRL) requesting an additional clinical study for the New Drug Application (NDA) of lifitegrast (Shire) for the signs and symptoms of dry eye disease in adults.

Dry Eyes: Updates on Risk Factors, Diagnosis, Tx

By August 28, 2015

As dry eyes is one of the most common reasons for patient visits to eye care professionals, the latest issue of the journal Optometry and Vision Science focuses on progress in the risk factors, diagnosis, and treatment of dry eye disease.

Particulate Matter Leads to Recall of Some Allergan Ophthalmic Products

August 24, 2015

Allergan plc. announced a voluntary recall of specific lots of REFRESH Lacri-Lube, REFRESH PM, FML (fluorometholone ophthalmic ointment) 0.1%, and Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment USP) 10%/0.2% due to the presence of particular matter.

Vitamin D Deficiency Tied to Dry Eye Syndromes

August 21, 2015

Vitamin D appears to play a protective role against the development of dry eye

Lifitegrast for Dry Eye Disease Under FDA Review

By April 13, 2015

The FDA has accepted for filing and granted Priority Review designation to the New Drug Application (NDA) for lifitegrast (Shire) for the treatment of signs and symptoms of dry eye disease in adults.

FDA to Review Lifitegrast for Dry Eye Disease

By March 02, 2015

Shire has submitted a New Drug Application (NDA) to the FDA for lifitegrast for the treatment of signs and symptoms of dry eye disease in adults.

Results Released for Dry Eye Trial with Lifitegrast

April 30, 2014

Shire announced results from its Phase 3 OPUS-2 study and Phase 3 SONATA safety study investigating lifitegrast (5.0% ophthalmic solution) in adults with dry eye disease.

Abrams Royal Pharmacy Recalls All Sterile Products

December 20, 2013

Abrams Royal Pharmacy is voluntarily recalling all unexpired lots of sterile products due to concerns of lack of sterility assurance.

Lifitegrast Effective for Dry Eyes in Trials

December 06, 2013

Shire announced top-line results from OPUS-2, a Phase 3 efficacy and safety study of 5.0% lifitegrast ophthalmic solution for dry eyes.

OTC Eye Drops Recalled Due to Possible Contamination

September 09, 2013

Altaire is voluntarily recalling nine lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution, an OTC product used to relieve dry eyes.

High Pain Sensitivity Linked to Dry Eye Disease Symptoms

August 02, 2013

Pain sensitivity and pain tolerance are associated with symptoms of dry eye disease (DED).